CMP Therapeutics appoints Dr Neill Moray Mackenzie

pharmafile | August 9, 2010 | Appointment | Research and Development CMP Therapeutics, appointment, research and development 

Dr Neill Moray Mackenzie has joined Hertfordshire, UK-based biopharmaceutical company CMP Therapeutics as chief executive.

He has a long record of executive board level management at companies that include Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore) and, most recently, Medigene, where he was senior vice president for business development and corporate strategy.

Dr MacKenzie has also served as a departmental head in vaccine R&D at Wellcome and as a Wellcome Lecturer in Immunology at the University of London.

Dr Achim Kaufhold, chairman of CMP, said: “Now is a pivotal time for the company as we move into advanced clinical development for our lead product and we are delighted to welcome Dr Mackenzie as chief executive.

“He combines proven experience in driving the corporate development of spin-outs from the Universities of Cambridge and Oxford with a highly relevant academic background in immunology and is ideally placed to ensure the rapid realisation of the value of our ground breaking technology.”

Meanwhile, CMP’s former chief executive Dr Bruce Savage leaves to concentrate on his other portfolio companies.

Related Content

sarah_mcdonald

Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

white_and_ford

Abbott CEO to step down after 21 years

After more than two decades at the head of the company, it has emerged that …

funk

Lonza CEO to step down in 2020

It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …

Latest content